Koji Sakamoto

Koji Sakamoto
Dr. Koji Sakamoto is Associate Professor in the Department of Respiratory Medicine at the Graduate School of Medicine, Nagoya University, Japan. He received his M.D. from Nagoya University in 2001 and earned his Ph.D. from the same institution in 2012. After several years of clinical training at Tosei General Hospital, a major referral center for interstitial lung diseases (ILDs) in Japan, he pursued postdoctoral research in pulmonary biology at Yale University. Dr. Sakamoto’s research focuses on the mechanisms underlying lung injury and pulmonary fibrosis, integrating clinical observations with translational investigation. His recent work has particularly focused on elucidating the pathogenesis of acute exacerbations of pulmonary fibrosis, identifying novel biomarkers, and exploring potential therapeutic targets. He has authored more than 100 peer-reviewed publications and has received several international honors, including the Pulmonary Fibrosis Foundation I.M. Rosenzweig Junior Investigator Award. He also contributes to national guideline development and scientific committees related to diffuse lung diseases.
Job Title
Associate Professor
Faculty / Department / Division
Faculty of Medicine, Department of Pulmonary Medicine
Institution / Organisation
Nagoya University

21 November 2026, Saturday

Time Session
14:00
15:30
Hsing-Chen Tsai Chairperson Taiwan
  • Arata Azuma Speaker Japan
  • Namkoong Ho Speaker Japan
    "Understanding host genetic susceptibility is crucial for unraveling the pathogenesis of infectious pulmonary diseases and developing personalized clinical strategies. In the first part of this presentation, we focus on severe COVID-19. Through a genome-wide association study (GWAS) in a Japanese cohort, we identified a risk variant at 5q35 (rs60200309-A) near DOCK2, which is associated with severe COVID-19 in patients under 65 years of age. Single-cell RNA sequencing and functional analyses revealed cell-type-specific downregulation of DOCK2 in non-classical monocytes, leading to impaired macrophage recruitment and dysregulated type I interferon responses. Importantly, this risk allele is prevalent in East Asians but rare in Europeans, underscoring the critical need for genetic studies in non-European populations(Namkoong, et al. Nature 2022.). In the second part, we transition to nontuberculous mycobacterial pulmonary disease (NTM-PD). By expanding our genomic investigation to multinational cohorts across Korea, Japan, and Europe, we identified and validated three susceptibility loci (IL1Rs, PDE8B, and PRKCB). Furthermore, Mendelian randomization analysis demonstrated a significant negative causal relationship between body mass index (BMI) and NTM-PD susceptibility(Park, et al. Am J Respir Crit Care Med . 2025). Together, these findings highlight that establishing multinational and multi-ethnic cohorts is indispensable for precision respirology, as it allows us to uncover both population-specific risk variants and globally conserved host mechanisms in respiratory infections."
  • Koji Sakamoto Speaker Japan
    Acute lung injury (ALI), including acute respiratory distress syndrome (ARDS), is a life-threatening syndrome triggered by systemic insults such as infection or trauma. It is characterized by intense pulmonary inflammation and increased vascular permeability that disrupt gas exchange. Despite decades of investigation, therapeutic strategies targeting aberrantly activated inflammatory cells, including corticosteroids, have produced inconsistent clinical benefits, underscoring the need for new mechanistic insights and therapeutic targets. Recent advances in innate immunology have begun to reveal pathways that regulate the dysregulated activation of phagocytes such as neutrophils and macrophages, highlighting previously unrecognized drivers of inflammatory tissue injury. In this lecture, I will discuss emerging mechanisms that amplify lung inflammation, with particular emphasis on inflammatory feedback loops between neutrophils and macrophages and on DNA-triggered inflammatory signaling pathways as potential drivers of organ injury, integrating insights from our recent studies.
  • Q&A
Ballroom 1, Lower Ground Floor